Amyloidosis (plural: amyloidoses) is a heterogeneous disease, or even considered a constellation of diseases, resulting in the deposition of relatively similar proteins. It has many causes and can affect any organ system.
The disease may have a male predilection. It typically affects middle-aged individuals around 60 years 5.
In view of the vast variety of clinical forms of amyloidosis, the potential spectrum of symptoms and signs is extremely broad, and can present in almost any way.
Amyloid comprises a group of proteins characterized by certain physical properties. There are at least 15 amyloid proteins, derived from diverse precursors. Some demonstrate the structural morphology of immunoglobulins, i.e. amyloid light chain.
- primary amyloidosis: associated with monoclonal plasma cell dyscrasias
- secondary amyloidosis: usually occurs secondary to a tissue destructive and inflammatory process
- hereditary amyloidosis: can be seen with familial Mediterranean fever (FMF)
- senile amyloidosis
- localized amyloidosis: sometimes classified as a separate entity with the above four accounting for the systemic forms
- dialysis-related amyloidosis 7: can occur with either haemodialysis or peritoneal dialysis
In certain scenarios, the amyloid proteins are produced and deposited locally, whereas in others, the protein is distributed systemically.
The majority occur in the systemic form:
- AL (amyloid light chain)
- synthesized by plasma cells, and seen in conditions with monoclonal proliferation of these cells
- AA (amyloid associated)
- derived from SAA (serum amyloid A) protein which is synthesized by the liver and forms part of the HDL3 lipoproteins
- typically seen in chronic inflammatory disease or familial Mediterranean fever
- Aß2M (amyloid ß2-microglobulin)
- derived from ß2-microglobulin
- seen in patients on haemodialysis or peritoneal dialysis
- hereditary (AApoA1) (apolipoprotein)
- hereditary (AFib) (mutant fibrinogen)
- hereditary (ALys) (lysozyme)
- ATTR (amyloid transthyretin)
- seen in senile systemic amyloidosis/neuropathic cerebral angiopathy
- is the most common form of familial amyloidosis 5
Accounts for ≈15% of amyloidosis:
- A4ß2 (beta-amyloid protein): seen in Alzheimer disease
- AANF (atrial natriuretic factor): isolated atrial amyloidosis
- AIAPP (islet amyloid peptide): deposited in the pancreas in patients with type II diabetes mellitus
- ACal: seen in medullary islet cell tumor
- Finnish-type (AGel) (Gelsolin); Lattice dystrophy of cornea, corneal neuropathy
Amyloid deposition can occur in any part of the body, although some are more common and have specific imaging findings. These conditions are best discussed separately:
- breast amyloidosis
- cardiac amyloidosis
- cerebral amyloid deposition diseases
- gastrointestinal amyloidosis
- hepatic amyloidosis
- pulmonary amyloidosis
- renal amyloidosis
- skeletal amyloidosis
- splenic amyloidosis
- tracheobronchial amyloidosis
- urinary tract amyloidosis
- laryngeal amyloidosis 9
Amyloid is an insoluble extracellular proteinaceous substance composed of cross-ß-pleated sheets which display apple-green birefringence when viewed under polarized light after being treated with Congo red stain 1.
- multiple myeloma (with primary amyloidosis)
History and etymology
The word “amylon” was first used in 1834 by the German botanist Matthias Schleiden to describe the waxy starch in plants.
Rudolph Virchow then coined the word “amyloid” in 1854 to describe tissue deposits that stained like cellulose when exposed to iodine.
- 1. Kumar V, Abbas AK, Fausto N et-al. Robbins and Cotran pathologic basis of disease. W B Saunders Co. (2005) ISBN:0721601871. Read it at Google Books - Find it at Amazon
- 2. Gilad R, Milillo P, Som PM. Severe diffuse systemic amyloidosis with involvement of the pharynx, larynx, and trachea: CT and MR findings. AJNR Am J Neuroradiol. 2007;28 (8): 1557-8. doi:10.3174/ajnr.A0604 - Pubmed citation
- 3. Georgiades CS, Neyman EG, Barish MA et-al. Amyloidosis: review and CT manifestations. Radiographics. 24 (2): 405-16. doi:10.1148/rg.242035114 - Pubmed citation
- 4. Urban BA, Fishman EK, Goldman SM et-al. CT evaluation of amyloidosis: spectrum of disease. Radiographics. 1993;13 (6): 1295-308. Radiographics (abstract) - Pubmed citation
- 5. Haaga JR, Boll D. CT and MRI of the whole body. Mosby. (2009) ISBN:0323053750. Read it at Google Books - Find it at Amazon
- 6. Czeyda-Pommersheim F, Hwang M, Chen SS, Strollo D, Fuhrman C, Bhalla S. Amyloidosis: Modern Cross-sectional Imaging. (2015) Radiographics : a review publication of the Radiological Society of North America, Inc. 35 (5): 1381-92. doi:10.1148/rg.2015140179 - Pubmed
- 7. Scarpioni R, Ricardi M, Albertazzi V, De Amicis S, Rastelli F, Zerbini L. Dialysis-related amyloidosis: challenges and solutions. (2016) International journal of nephrology and renovascular disease. 9: 319-328. doi:10.2147/IJNRD.S84784 - Pubmed
- 8. Baker KR, Rice L. The amyloidoses: clinical features, diagnosis and treatment. (2012) Methodist DeBakey cardiovascular journal. 8 (3): 3-7. doi:10.14797/mdcj-8-3-3 - Pubmed
- 9. Burns H, Burns PN, Burns. Laryngeal amyloidosis. (2019) Current opinion in otolaryngology & head and neck surgery. doi:10.1097/MOO.0000000000000579 - Pubmed